# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number: k173127   
B. Purpose for Submission: New Device   
C. Measurand: Whole blood glycosylated hemoglobin (HbA1c)   
D. Type of Test: Quantitative immunoassay with latex agglutination   
E. Applicant: Skyla Corporation H.S.P.B.

# F. Proprietary and Established Names:

skyla Hi Hemoglobin A1c System (skyla Hi Analyzer and skyla Hi Hemoglobin A1c Reagent Kit)

# G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LCP</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 864.7470Glycosylated hemoglobin assay</td><td rowspan=1 colspan=1>Hematology(81)</td></tr><tr><td rowspan=1 colspan=1>JJE</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.2160Discrete photometric chemistryanalyzer</td><td rowspan=1 colspan=1>Chemistry(75)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

See indications for use below

2. Indication(s) for use:

The skyla Hi Hemoglobin A1c System, consisting of the skyla Hi Analyzer and skyla Hi Hemoglobin A1c Reagent Kit is an in-vitro diagnostic test for quantitative measurement of the percent concentration $( \% )$ of glycated hemoglobin (HbA1c $\%$ ) in venous and finger-stick capillary whole blood.

The measurement of $\%$ HbA1c is used to monitor long-term glycemic control in persons previously diagnosed with diabetes mellitus.

This system is intended for clinical laboratory and point-of-care use.

This test is not for screening or diagnosis of diabetes.

3. Special conditions for use statement(s):

For prescription use only   
This test is not for screening or diagnosis of diabetes or neonatal use   
Use fresh whole blood only. Do not use plasma and serum.   
When testing venous whole blood, test only samples collected in K3-EDTA   
The test is not intended for judging day-to-day glucose control and should not be used to replace daily home testing of urine or blood glucose.   
This test should not be used for analyzing samples from patients with conditions causing shortened red blood cell survival, such as hemolytic diseases, homozygous sickle cell trait, pregnancy and significant acute or chronic blood loss   
Hemoglobinopathies may interfere with glycated hemoglobin analysis. The results from the skyla Hi Hemoglobin A1c show that there is no significant interference for Hemoglobin C $: ( \leq 3 6 \% )$ , Hemoglobin D $( \leq 4 2 \% )$ , Hemoglobin E $( \leq 2 6 \% )$ ,   
Hemoglobin S $( \leq 4 1 \% )$ . High Hemoglobin $\mathrm { F } \left( > 1 1 \% \right)$ will result in lower than expected HbA1c values. High HbA2 $( > 5 . 7 \% )$ will result in higher than expected expected HbA1c values.

4. Special instrument requirements: skyla Hi Analyzer

# I. Device Description:

The skyla Hi Hemoglobin A1c System consists of the skyla Hi Hemoglobin A1c Reagent that is tested using the skyla Hi Analyzer. Each skyla Hi Hemoglobin A1c Reagent Kit includes an analysis cartridge and a reagent pack containing the following components:

Reagent Pack: Cell Lysis Buffer (surfactant agent dissolved in a buffer), latex solution (latex particles dissolved in a buffer) Analysis Cartridge: HbA1c specific mouse monoclonal antibodies and rabbit anti-mouse polyclonal antibodies dissolved in a buffer and then freeze-dried into spherical beads.

The specimen is collected through a capillary tube on the reagent pack before testing. The skyla Hi Analyzer can run up to two skyla Hi Hemoglobin A1c Reagent Kits at the same time. If a single skyla Hi Hemoglobin A1c Reagent Kit will be run, then a dummy balancer (black balancer of similar dimensions to the skyla Hi Hemoglobin A1c Reagent Kit) should be used in the machine.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Afinion AS100 Analyzer Afinion HbA1c

2. Predicate 510(k) number(s): k151809

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate Deviceskyla Hi Hemoglobin A1cSystem System (skyla HiAnalyzer and skyla HiHemoglobin A1c Reagent Kit)(k173127)</td><td colspan="1" rowspan="1">Predicate DeviceAfinion HbA1c/Afinion AS100Analyzer(k151809)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Intended for the quantitativemeasurement of the percentconcentration (%) of glycatedhemoglobin (HbA1c %) invenous and finger-stickcapillary whole blood.The measurement of % HbA1cis used to monitor long-termglycemic control in personspreviously diagnosed withdiabetes mellitus.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Intended users</td><td colspan="1" rowspan="1">Laboratory professionals andpoint-of-care users</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Whole blood: finger-stickcapillary and venous</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Method of Sampling</td><td colspan="1" rowspan="1">Blood is collected with acapillary tube in the reagentpack, and the sampling device</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">is inserted into the cartridge</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Method Traceability orStandardization</td><td colspan="1" rowspan="1">National GlycohemoglobinStandardization Program(NGSP)</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate Deviceskyla Hi Hemoglobin A1cSystem (skyla Hi Analyzerand skyla Hi HemoglobinAlc Reagent Kit)(k173127)</td><td rowspan=1 colspan=1>Predicate DeviceAfinion HbA1c/Afinion AS100Analyzers(k151809)</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Immunoassay using latexagglutination</td><td rowspan=1 colspan=1>Boronate affinity assay</td></tr><tr><td rowspan=1 colspan=1>Sampling Device capillarymaterial</td><td rowspan=1 colspan=1>Glass</td><td rowspan=1 colspan=1>Plastic</td></tr><tr><td rowspan=1 colspan=1>Fill volume of samplingdevice capillary</td><td rowspan=1 colspan=1>0.8 uL</td><td rowspan=1 colspan=1>1.5 uL</td></tr><tr><td rowspan=1 colspan=1>Time to result</td><td rowspan=1 colspan=1>6 minutes</td><td rowspan=1 colspan=1>3 minutes</td></tr><tr><td rowspan=1 colspan=1>Sample anticoagulant type</td><td rowspan=1 colspan=1>K3-EDTA</td><td rowspan=1 colspan=1>EDTA, heparin, citrate</td></tr><tr><td rowspan=1 colspan=1>Measuring Interval</td><td rowspan=1 colspan=1>4-14% HbA1c</td><td rowspan=1 colspan=1>4-15% HbA1c</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

IEC 60601-1-2: Medical Electrical Equipment - Part 1-2: General Requirements For Basic Safety And Essential Performance - Collateral Standard: Electromagnetic Disturbances - Requirements And Tests

CLSI EP05-A3: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline- Third Edition

CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline.

CLSI EP07-A2: Interference Testing In Clinical Chemistry; Approved Guideline - Second Edition

CLSI EP17-A2: Evaluation Of Detection Capability For Clinical Laboratory Measurement

Procedures; Approved Guideline -- Second Edition

CLSI EP25-A: Evaluation Of Stability Of In Vitro Diagnostic Reagents; Approved Guideline. (In-Vitro Diagnostics)

# L. Test Principle:

The assay principle is based on immunoturbidimetric measurement of a monoclonal antibody agglutination reaction. Through a latex reagent, all hemoglobin can nonspecifically adhere to a latex sphere. Following addition of the HbA1c specific monoclonal antibody, the latex sphere will produce agglutination reaction, and the agglutination causes increased scattering of light, which is measured as an increase in absorbance at $6 5 0 \mathrm { n m }$ . The HbA1c concentration is then quantified using a calibration curve of absorbance versus HbA1c concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Internal Precision   
The sponsor conducted an internal precision study according to CLSI EP05-A3, using three skyla Hi Analyzers and three lots of skyla Hi Hemoglobin A1c Reagent Kit. Three quality control (QC) samples and eight human venous whole blood (WB) samples (K3-EDTA) were measured over 20 days. The protocol consisted of   
measuring the sample material in duplicate in two runs per day for 20 days producing $\scriptstyle \mathrm { n = 8 0 }$ results per sample per lot for a total of 240 results per sample. The within-run, between-run, between-day and total precision were calculated (SD and $\% C V$ ). The results are summarized below in NGSP units (%HbA1c):

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Within-Run</td><td colspan="2" rowspan="1">BetweenRun</td><td colspan="2" rowspan="1">Between Day</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Sample*</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">MeanHbA1c%</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td></tr><tr><td colspan="1" rowspan="1">QC 1</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">5.13</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.8%</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.13</td><td colspan="1" rowspan="1">2.5%</td></tr><tr><td colspan="1" rowspan="1">QC 2</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">9.72</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">2.0%</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">1.8%</td><td colspan="1" rowspan="1">0.28</td><td colspan="1" rowspan="1">2.9%</td></tr><tr><td colspan="1" rowspan="1">QC 3</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">13.51</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">1.2%</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.2%</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1">2.4%</td></tr><tr><td colspan="1" rowspan="1">WB 1</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">5.23</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.5%</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">2.1%</td></tr><tr><td colspan="1" rowspan="1">WB 2</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">5.51</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.4%</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.1%</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">WB 3</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">7.63</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">2.0%</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">0.7%</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">2.4%</td></tr><tr><td colspan="1" rowspan="1">WB 4</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">9.93</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">1.0%</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">1.2%</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">2.3%</td></tr><tr><td colspan="1" rowspan="1">WB 5</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">11.98</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">1.6%</td></tr><tr><td colspan="1" rowspan="1">WB 6</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">5.00</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">0.2%</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.1%</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">WB 7</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">6.47</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">1.8%</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.4%</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">1.0%</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">2.1%</td></tr><tr><td colspan="1" rowspan="1">WB 8</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">7.99</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">2.0%</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">2.2%</td></tr></table>

${ } ^ { * } \mathrm { W } \mathrm { B } =$ Venous Whole Blood (K3-EDTA) $\mathbf { Q C } =$ Quality Control Material

# External Precision (Point-of-Care)

An external precision study was conducted at three point-of-care (POC) sites. There were three operators at each site, for a total of nine operators. At each site, the samples were measured in duplicate two times a day twice a day for 20 days at three sites. Within run (repeatability), between-run, between day, and total reproducibility (SD and percent CVs) were calculated. Each site had 80 results for a total of 240 results per sample across all three sites.

Each POC site assessed one lot of skyla Hi Hemoglobin A1c Reagent Kit using one skyla Hi HbA1c analyzer, for a total of three lots and three analyzers at three sites. Three quality control (QC) samples and five human venous whole blood (WB) samples (K3-EDTA) were tested.

The within-run, between-run, between-day and total precision were calculated (SD and $\% C V$ ), for each site and all three sites. The results are summarized below in NGSP units (%HbA1c):

<table><tr><td colspan="1" rowspan="2">Sample*</td><td colspan="1" rowspan="2">Site</td><td colspan="1" rowspan="2">MeanHbA1c%</td><td colspan="2" rowspan="1">Repeatability(Within-Run)</td><td colspan="2" rowspan="1">Between Run</td><td colspan="2" rowspan="1">Between Day</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td></tr><tr><td colspan="1" rowspan="4">WB 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">5.04</td><td colspan="1" rowspan="1">0.097</td><td colspan="1" rowspan="1">1.9%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.032</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.103</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">5.06</td><td colspan="1" rowspan="1">0.082</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.039</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">0.034</td><td colspan="1" rowspan="1">0.7%</td><td colspan="1" rowspan="1">0.097</td><td colspan="1" rowspan="1">1.9%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">5.03</td><td colspan="1" rowspan="1">0.075</td><td colspan="1" rowspan="1">1.5%</td><td colspan="1" rowspan="1">0.062</td><td colspan="1" rowspan="1">1.2%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.097</td><td colspan="1" rowspan="1">1.9%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">5.04</td><td colspan="1" rowspan="1">0.085</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.038</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">0.014</td><td colspan="1" rowspan="1">0.3%</td><td colspan="1" rowspan="1">0.095</td><td colspan="1" rowspan="1">1.9%</td></tr><tr><td colspan="1" rowspan="4">WB 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">5.55</td><td colspan="1" rowspan="1">0.097</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.045</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.107</td><td colspan="1" rowspan="1">1.9%</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">5.59</td><td colspan="1" rowspan="1">0.095</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.032</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.100</td><td colspan="1" rowspan="1">1.8%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">5.56</td><td colspan="1" rowspan="1">0.100</td><td colspan="1" rowspan="1">1.8%</td><td colspan="1" rowspan="1">0.065</td><td colspan="1" rowspan="1">1.2%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.119</td><td colspan="1" rowspan="1">2.1%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">5.56</td><td colspan="1" rowspan="1">0.097</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.049</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.110</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="4">WB 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">6.57</td><td colspan="1" rowspan="1">0.105</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.062</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">0.057</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">0.134</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">6.53</td><td colspan="1" rowspan="1">0.111</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.086</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.141</td><td colspan="1" rowspan="1">2.2%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">6.54</td><td colspan="1" rowspan="1">0.110</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.057</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">0.040</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.130</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">6.54</td><td colspan="1" rowspan="1">0.109</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.070</td><td colspan="1" rowspan="1">1.1%</td><td colspan="1" rowspan="1">0.038</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.135</td><td colspan="1" rowspan="1">2.1%</td></tr><tr><td colspan="1" rowspan="4">WB 4</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">7.93</td><td colspan="1" rowspan="1">0.126</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.099</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.067</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">0.174</td><td colspan="1" rowspan="1">2.2%</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">7.95</td><td colspan="1" rowspan="1">0.132</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.112</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.112</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.207</td><td colspan="1" rowspan="1">2.6%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">7.99</td><td colspan="1" rowspan="1">0.150</td><td colspan="1" rowspan="1">1.9%</td><td colspan="1" rowspan="1">0.097</td><td colspan="1" rowspan="1">1.2%</td><td colspan="1" rowspan="1">0.115</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.212</td><td colspan="1" rowspan="1">2.7%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">7.96</td><td colspan="1" rowspan="1">0.137</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.103</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.100</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.198</td><td colspan="1" rowspan="1">2.5%</td></tr><tr><td colspan="1" rowspan="4">WB 5</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">12.07</td><td colspan="1" rowspan="1">0.243</td><td colspan="1" rowspan="1">2.0%</td><td colspan="1" rowspan="1">0.188</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.308</td><td colspan="1" rowspan="1">2.5%</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">12.10</td><td colspan="1" rowspan="1">0.250</td><td colspan="1" rowspan="1">2.1%</td><td colspan="1" rowspan="1">0.189</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.313</td><td colspan="1" rowspan="1">2.6%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">12.13</td><td colspan="1" rowspan="1">0.212</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.138</td><td colspan="1" rowspan="1">1.1%</td><td colspan="1" rowspan="1">0.096</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">0.270</td><td colspan="1" rowspan="1">2.2%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">12.10</td><td colspan="1" rowspan="1">0.236</td><td colspan="1" rowspan="1">2.0%</td><td colspan="1" rowspan="1">0.173</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.292</td><td colspan="1" rowspan="1">2.4%</td></tr><tr><td colspan="1" rowspan="1">QC 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">5.24</td><td colspan="1" rowspan="1">0.092</td><td colspan="1" rowspan="1">1.8%</td><td colspan="1" rowspan="1">0.085</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.033</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.130</td><td colspan="1" rowspan="1">2.5%</td></tr><tr><td colspan="1" rowspan="5">Sample*</td><td colspan="1" rowspan="2">Site</td><td colspan="1" rowspan="2">MeanHbA1c%</td><td colspan="2" rowspan="1">Repeatability(Within-Run)</td><td colspan="2" rowspan="1">Between Run</td><td colspan="2" rowspan="1">Between Day</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">5.18</td><td colspan="1" rowspan="1">0.115</td><td colspan="1" rowspan="1">2.2%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.055</td><td colspan="1" rowspan="1">1.1%</td><td colspan="1" rowspan="1">0.128</td><td colspan="1" rowspan="1">2.5%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">5.20</td><td colspan="1" rowspan="1">0.118</td><td colspan="1" rowspan="1">2.3%</td><td colspan="1" rowspan="1">0.067</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.136</td><td colspan="1" rowspan="1">2.6%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">5.20</td><td colspan="1" rowspan="1">0.109</td><td colspan="1" rowspan="1">2.1%</td><td colspan="1" rowspan="1">0.060</td><td colspan="1" rowspan="1">1.2%</td><td colspan="1" rowspan="1">0.029</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.130</td><td colspan="1" rowspan="1">2.5%</td></tr><tr><td colspan="1" rowspan="4">QC 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">9.70</td><td colspan="1" rowspan="1">0.200</td><td colspan="1" rowspan="1">2.1%</td><td colspan="1" rowspan="1">0.142</td><td colspan="1" rowspan="1">1.5%</td><td colspan="1" rowspan="1">0.143</td><td colspan="1" rowspan="1">1.5%</td><td colspan="1" rowspan="1">0.284</td><td colspan="1" rowspan="1">2.9%</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">9.71</td><td colspan="1" rowspan="1">0.208</td><td colspan="1" rowspan="1">2.1%</td><td colspan="1" rowspan="1">0.022</td><td colspan="1" rowspan="1">0.2%</td><td colspan="1" rowspan="1">0.096</td><td colspan="1" rowspan="1">1.0%</td><td colspan="1" rowspan="1">0.230</td><td colspan="1" rowspan="1">2.4%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">9.68</td><td colspan="1" rowspan="1">0.228</td><td colspan="1" rowspan="1">2.4%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.171</td><td colspan="1" rowspan="1">1.8%</td><td colspan="1" rowspan="1">0.285</td><td colspan="1" rowspan="1">3.0%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">9.69</td><td colspan="1" rowspan="1">0.213</td><td colspan="1" rowspan="1">2.2%</td><td colspan="1" rowspan="1">0.052</td><td colspan="1" rowspan="1">0.5%</td><td colspan="1" rowspan="1">0.140</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.260</td><td colspan="1" rowspan="1">2.7%</td></tr><tr><td colspan="1" rowspan="4">QC 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">13.59</td><td colspan="1" rowspan="1">0.085</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.100</td><td colspan="1" rowspan="1">0.7%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.131</td><td colspan="1" rowspan="1">1.0%</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">13.57</td><td colspan="1" rowspan="1">0.084</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.132</td><td colspan="1" rowspan="1">1.0%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.156</td><td colspan="1" rowspan="1">1.2%</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">13.60</td><td colspan="1" rowspan="1">0.081</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.094</td><td colspan="1" rowspan="1">0.7%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.124</td><td colspan="1" rowspan="1">0.9%</td></tr><tr><td colspan="1" rowspan="1">All</td><td colspan="1" rowspan="1">13.58</td><td colspan="1" rowspan="1">0.083</td><td colspan="1" rowspan="1">0.6%</td><td colspan="1" rowspan="1">0.110</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.138</td><td colspan="1" rowspan="1">1.0%</td></tr></table>

${ } ^ { * } \mathrm { W } \mathrm { B } =$ Venous Whole Blood (K3-EDTA) $\mathbf { Q C } =$ Quality Control Material

# b. Linearity/assay reportable range:

Linearity was evaluated according to CLSI EP06-A. Test sample pools were prepared by diluting test sample pools of human venous whole blood (WB) samples (K3- EDTA) containing high $( 1 5 \% )$ and low $( 4 . 1 \% )$ concentrations of HbA1c to create nine levels of test sample pools. The assigned value of each of the nine (9) levels was determined by a clinical lab. Each test sample pool was tested in quadruplicate with one reagent lot using the skyla Hi Hemoglobin A1c System, and then analyzed using the best-fitting polynomial. The targeted assigned values of each level were measured by a clinical lab. The deviation between polynomial fit and line fit results were determined. The following concentrations of HbA1c were tested.

NGSP Units $( \%$ HbA1c)   

<table><tr><td rowspan=1 colspan=1>No.</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>%HbA1cConc.</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>14.1</td><td rowspan=1 colspan=1>15</td></tr></table>

The linear regression results are in the table below:

NGSP Units (%HbA1c)   

<table><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>RegressionCoefficient(R{)</td><td rowspan=1 colspan=1>CaimedMeasuringInterval</td></tr><tr><td rowspan=1 colspan=1>0.9665</td><td rowspan=1 colspan=1>0.3506</td><td rowspan=1 colspan=1>0.9939</td><td rowspan=1 colspan=1>4-14% HbA1c</td></tr></table>

The linearity results support the sponsor’s claims that the assay is linear across the reportable measuring interval of 4 to $14 \%$ HbA1c.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability

The skyla Hi Hemoglobin A1c Reagent Kit is traceable to the Diabetes Control and Complications Trial Reference Method. The device is certified with the National Glycohemoglobin Standardization Program (NGSP). The certification expires in one year. See NGSP website for current certification at http://www.ngsp.org.

# d. Detection limit:

The limit of blank (LoB) and limit of detection (LoD) were determined in accordance with CLSI EP17-A. The LoB and LoD values were determined by measuring 180 blank measurements and 180 low-level HbA1c measurement. To determine LoB and LoD, 5 blank and 5 whole blood low level samples each were tested using 2 reagent lots and 1 instrument system. Testing was performed for 3 days at 4 replicates per day for a total of 60 measurements per reagent lot (120 measurements total per LoB and LoD). The LoB and LoD results are listed below:

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td></tr><tr><td rowspan=1 colspan=1>HbA1c (%)</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.6%</td></tr></table>

e. Analytical specificity:

# Endogenous Interferences

An interference study was performed using the skyla Hi Hemoglobin A1c System to assess the effect of common endogenous interferents. The interference study was conducted according to CLSI guideline EP07-A2. One lot of skyla Hi Hemoglobin A1c Reagent Kit and 1 skyla Hi Analyzer was used in the study. The sample pool material was K3-EDTA venous whole blood with a concentration of approximately $5- 6 \%$ HbA1c and approximately $9 . 1 0 \%$ HbA1c. Two sample pools were prepared for each potential endogenous interferent, with or without interferent (serving as the reference or control sample). The spiked and control pools were mixed in different ratios to yield a dilution series with varying concentrations of the interferent. Each sample was tested in triplicate and the mean value was used for the assessment. The sponsor defined non-significant interference $\leq \pm 6 \%$ deviation compared to the result of the control pool. The table below summarizes the results of this study:

<table><tr><td colspan="1" rowspan="1">Endogenous Substance</td><td colspan="1" rowspan="1">Highest Level Testedwith no SignificantInterference</td></tr><tr><td colspan="1" rowspan="1">Conjugated Bilirubin</td><td colspan="1" rowspan="1">60.2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Unconjugated Bilirubin</td><td colspan="1" rowspan="1">60.2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Lipemia/Intralipid</td><td colspan="1" rowspan="1">6110 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Urea</td><td colspan="1" rowspan="1">282 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">2800mg/dL</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Factor (RF)</td><td colspan="1" rowspan="1">1200IU/mL</td></tr><tr><td colspan="1" rowspan="1">Total Protein</td><td colspan="1" rowspan="1">22800mg/dL</td></tr><tr><td colspan="1" rowspan="1">Albumin</td><td colspan="1" rowspan="1">9500mg/dL</td></tr><tr><td colspan="1" rowspan="1">Glycated albumin</td><td colspan="1" rowspan="1">770 mg/dL</td></tr></table>

# Exogenous Interferences

An interference study was performed using the skyla Hi Hemoglobin A1c System to assess the effect of common exogenous interferents. The interference study was conducted according to CLSI guideline EP07-A2. One lot of skyla Hi Hemoglobin A1c Reagent Kit and 1 skyla Hi Analyzer was used in the study. The sample pool material was K3-EDTA venous whole blood with a concentration of approximately $5- 6 \%$ HbA1c and approximately $9 . 1 0 \%$ HbA1c. Two sample pools were prepared for each potential endogenous interferent, with or without interferent (serving as the reference or control sample). The reference or control samples were spiked with equivalent volume of diluent used to prepare the interferent-spiking samples. Each sample was tested in triplicate and the mean value was used for the assessment. The sponsor defined non-significant interference $\leq \pm 6 \%$ deviation compared to the result of the reference pool. The table below summarizes the results of this study:

<table><tr><td rowspan=1 colspan=1>Exogenous Interference</td><td rowspan=1 colspan=1>Highest Level Tested withNo Significant Interference(≤± 6%)</td></tr><tr><td rowspan=1 colspan=1>Aspirin (Acetylsalicylic acid)</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylcysteine</td><td rowspan=1 colspan=1>166 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>250 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine A</td><td rowspan=1 colspan=1>1 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine C</td><td rowspan=1 colspan=1>1 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Doxcycyline</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glyburide</td><td rowspan=1 colspan=1>0.2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5000 U/dL</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Levodopa (L-dopa)</td><td rowspan=1 colspan=1>2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metformin</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>6.4 mg/dL</td></tr></table>

Cross-Reactivity with Hemoglobin Derivatives   

<table><tr><td rowspan=1 colspan=1>Exogenous Interference</td><td rowspan=1 colspan=1>Highest Level Tested withNo Significant Interference(≤± 6%)</td></tr><tr><td rowspan=1 colspan=1>Salicylic acid</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>10 mg/dL</td></tr></table>

A study was performed using the skyla Hi Hemoglobin A1c System to assess the effect of hemoglobin derivatives on measurement of HbA1c. One lot of skyla Hi Hemoglobin A1c Reagent Kit and one skyla Hi Analyzer was used in the study. The sample pool material was K3-EDTA venous whole blood with a concentration of approximately 5-6 $\%$ HbA1c and approximately $9 . 1 0 \%$ HbA1c. Two sample pools were prepared for each potential endogenous interferent, with or without interferent (serving as the reference or control sample). The spiked and control pools were mixed in different ratios to yield a dilution series with varying concentrations of the hemoglobin derivatives. Each sample was tested in triplicate and the mean value was used for the assessment. The sponsor defined non-significant interference $\leq \pm 6 \%$ deviation compared to the result of the reference pool. The table below summarizes the results of this study:

<table><tr><td rowspan=1 colspan=1>Hemoglobin Derivative</td><td rowspan=1 colspan=1>Highest Level Tested withNo Significant Interference(≤± 6%)</td></tr><tr><td rowspan=1 colspan=1>Acetylated hemoglobin</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Carbamylated hemoglobin</td><td rowspan=1 colspan=1>600mg/dL</td></tr><tr><td rowspan=1 colspan=1>Labile hemoglobin</td><td rowspan=1 colspan=1>3000mg/dL</td></tr><tr><td rowspan=1 colspan=1>HbA1a+b</td><td rowspan=1 colspan=1>16 mg/dL</td></tr><tr><td rowspan=1 colspan=1>HbA0</td><td rowspan=1 colspan=1>1200 mg/dL</td></tr></table>

# Hemoglobin Variant Interference

A study was performed using the skyla Hi Hemoglobin A1c Sytem to assess the effect of common hemoglobin variants on the measurement of HbA1c. One lot of skyla Hi Hemoglobin A1c Reagent Kit and one skyla Hi Analyzer was used in the study. 55 venous whole blood samples with known target values of HbA1c and variant concentrations (assigned by IFCC and NGSP) were tested in duplicate. The venous whole blood samples (concentrations ranging between 4.1 and $1 4 . 0 \%$ HbA1c) contained known levels of hemoglobin variants A2, C, D, E, F and S. Between 4 and 11 samples per hemoglobin variant were tested in duplicate using the skyla Hi Hemoglobin A1c System for $\%$ HbA1c results. The sponsor defined non-significant interference $\leq \pm 7 \%$ deviation compared to the result of the assigned value. The table below summarizes the results of this study:

<table><tr><td>Hemoglobin Variant</td><td>Highest Level Tested with No Significant Interference (≤± 7%)</td></tr><tr><td>HbA2</td><td>5.7%</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin Variant</td><td colspan="1" rowspan="1">Highest Level Tested withNo Significant Interference(≤±7%)</td></tr><tr><td colspan="1" rowspan="1">HbC</td><td colspan="1" rowspan="1">36%</td></tr><tr><td colspan="1" rowspan="1">HbD</td><td colspan="1" rowspan="1">42%</td></tr><tr><td colspan="1" rowspan="1">HbE</td><td colspan="1" rowspan="1">26%</td></tr><tr><td colspan="1" rowspan="1">HbF</td><td colspan="1" rowspan="1">11%</td></tr><tr><td colspan="1" rowspan="1">HbS</td><td colspan="1" rowspan="1">41%</td></tr></table>

The sponsor’s labeling includes the following limitation:

"Hemoglobinopathies may interfere with glycated hemoglobin analysis. The results from the skyla Hi Hemoglobin A1c System show that there is no significant interference for Hemoglobin C $( \leq 3 6 \% )$ , Hemoglobin D $( \leq 4 2 \% )$ , Hemoglobin E $( \leq 2 6 \% )$ , Hemoglobin S $( \leq 4 1 \% )$ . High Hemoglobin F $( > 1 1 \% )$ will result in lower than expected HbA1c values. High HbA2 $\mathrm { ( > 5 . 7 \% ) }$ will result in higher than expected expected HbA1c values.”

$f .$ Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device:

A method comparison study was conducted at four point of care testing sites. Venous K3-EDTA whole blood and capillary finger-stick blood samples were collected from each patient $( \mathrm { n } { = } 2 4 3$ venous whole blood and $\mathrm { n } { = } 2 4 3$ capillary finger-stick samples) and tested in singlicate using the skyla Hi Hemoglobin A1c System (five analyzers) and compared to matched venous K3-EDTA venous whole blood measured using the Bio-Rad VARIANT II Turbo System in a clinical laboratory. Each of the four pointof-care sites included between three and five operators, for a total of 16 operators. Between one to four reagent kit lots were used at each site for this study. The range of HbA1c tested was 4.8 to $1 3 . 2 \%$ HbA1c. The best fit linear regression results are listed in the tables below in NGSP Units (%HbA1c):

<table><tr><td rowspan=2 colspan=2>HbA1c</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>R2</td><td rowspan=2 colspan=1>Slope</td><td rowspan=2 colspan=1>Intercept</td><td rowspan=1 colspan=2>Sample Range</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=4 colspan=1>VenousWholeBlood</td><td rowspan=1 colspan=1>POC Site 1</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.9844</td><td rowspan=1 colspan=1>0.9930</td><td rowspan=1 colspan=1>0.0794</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>13.2</td></tr><tr><td rowspan=1 colspan=1>POC Site 2</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.9853</td><td rowspan=1 colspan=1>1.0001</td><td rowspan=1 colspan=1>0.0733</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>12.6</td></tr><tr><td rowspan=1 colspan=1>POC Site 3</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>0.9819</td><td rowspan=1 colspan=1>0.9882</td><td rowspan=1 colspan=1>0.1013</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>13.0</td></tr><tr><td rowspan=1 colspan=1>POC Site 4</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>0.9903</td><td rowspan=1 colspan=1>0.9963</td><td rowspan=1 colspan=1>0.0636</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>9.4</td></tr></table>

<table><tr><td rowspan=3 colspan=2>HbA1cCombined</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>R2</td><td rowspan=2 colspan=1>Slope</td><td rowspan=2 colspan=1>Intercept</td><td rowspan=1 colspan=2>Sample Range</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>0.9858</td><td rowspan=1 colspan=1>0.9945</td><td rowspan=1 colspan=1>0.0779</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>13.2</td></tr><tr><td rowspan=5 colspan=1>Finger-stickCapillaryBlood</td><td rowspan=1 colspan=1>POC Site 1</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.9831</td><td rowspan=1 colspan=1>1.0010</td><td rowspan=1 colspan=1>-0.0075</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>13.2</td></tr><tr><td rowspan=1 colspan=1>POC Site 2</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.9850</td><td rowspan=1 colspan=1>1.0036</td><td rowspan=1 colspan=1>0.1193</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>12.5</td></tr><tr><td rowspan=1 colspan=1>POC Site 3</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>0.9811</td><td rowspan=1 colspan=1>0.9810</td><td rowspan=1 colspan=1>0.1871</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>13.1</td></tr><tr><td rowspan=1 colspan=1>POC Site 4</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>0.9804</td><td rowspan=1 colspan=1>0.9850</td><td rowspan=1 colspan=1>0.1111</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>0.9841</td><td rowspan=1 colspan=1>0.9993</td><td rowspan=1 colspan=1>0.0589</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>13.2</td></tr></table>

$b$ . Matrix comparison: Not applicable. The sponsor’s only claimed anticoagulant is K3-EDTA.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The sponsor provides the following expected values in their labeling:

In 2018, the American Diabetes Association (ADA) recommended a reasonable A1c goal for many non-pregnant adults is $< 7 ~ \%$ $\mathrm { 5 3 ~ m m o l / m o l ) }$ . Providers might reasonably suggest more stringent A1C goals (such as $6 . 5 \%$ $[ 4 8 \mathrm { m m o l / m o l } ] )$ for selected individual patients if this can be achieved without significant hypoglycemia or other adverse effects of treatment\*”.

\*American Diabetes Association. Standards of Medical Care in Diabetes-2018.   
Diabetes Care. 2018 Jan; 41 Suppl. 1: S55-S64.

N. Instrument Name: skyla Hi Analyzer

# O. System Descriptions:

1. Modes of Operation:

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?

Yes __x_ _ or No

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?

Yes _ or No ___x_

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes ___x_ _ or No

3. Specimen Identification:

Patient information can be entered manually on the device or patient record information can be entered using an optional externally connected barcode scanner, via USB interface.

4. Specimen Sampling and Handling:

The sample is applied directly from the fingerstick. If using venous whole blood, a drop of blood should be removed from the collection tube, placed on a clean container or slide, and collected using the glass capillary tube on the reagent pack. After application of the sample to the reagent pack capillary, the operator places the reagent pack into the analysis cartridge. The cartridge is then inserted into the instrument. There are no preanalytical steps needed after the blood sample is taken using the sample capillary.

# 5. Calibration:

The analyzer automatically reads in the lot-specific calibration data from the barcode information printed on the analysis cartridge, eliminating the need for calibration by the user

# 6. Quality Control:

The recommended quality control material is BIO-RAD Lyphochek Diabetes Control, Level 1 and Level 2. The frequency and criteria of quality control testing should be adapted to each site’s individual requirements.

# P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above:

Postmarket information for this device and device type was considered during the review of this submission.

# Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 809.10.

# R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.